This is a working overview of 胰高血糖素受体, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-29. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
=== EC 1.14.12 With NADH or NADPH as one donor, and incorporation of two atoms of oxygen into one donor === EC 1.14.12.1: anthranilate 1,2-dioxygenase (deaminating, decarboxylating) EC 1.14.12.2: Now EC 1.14.13.35 anthranilate 3-monooxygenase (deaminating) EC 1.14.12.3: benzene 1,2-dioxygenase EC 1.14.12.4: EC 1.14.13.242, 3-hydroxy-2-methylpyridinecarboxylate monooxygenase EC 1.14.12.5: Now EC .14.13.241, 5-pyridoxate monooxygenase EC 1.14.12.6: Now EC 1.14.13.66, 2-hydroxycyclohexanone 2-monooxygenase EC 1.14.12.7: phthalate 4,5-dioxygenase EC 1.14.12.8: 4-sulfobenzoate 3,4-dioxygenase EC 1.14.12.9: 4-chlorophenylacetate 3,4-dioxygenase EC 1.14.12.10: benzoate 1,2-dioxygenase EC 1.14.12.11: toluene dioxygenase EC 1.14.12.12: naphthalene 1,2-dioxygenase EC 1.14.12.13: 2-halobenzoate 1,2-dioxygenase EC 1.14.12.14: 2-aminobenzenesulfonate 2,3-dioxygenase EC 1.14.12.15: terephthalate 1,2-dioxygenase EC 1.14.12.16: 2-hydroxyquinoline 5,6-dioxygenase EC 1.14.12.17: nitric oxide dioxygenase EC 1.14.12.18: biphenyl 2,3-dioxygenase EC 1.14.12.19: 3-phenylpropionate dioxygenase EC 1.14.12.20: Now classified as EC 1.14.15.17, pheophorbide a oxygenase. EC 1.14.12.21: Now EC 1.14.13.208, benzoyl-CoA 2,3-epoxidase EC 1.14.12.22: carbazole 1,9a-dioxygenase EC 1.14.12.23: nitroarene dioxygenase EC 1.14.12.24: 2,4-dinitrotoluene dioxygenase EC 1.14.12.25: p-cumate 2,3-dioxygenase EC 1.14.12.26: chlorobenzene dioxygenase
Drotrecogin should only be ordered by a critical care specialist with experience weighing the risks and benefits of this medication. Drotrecogin should only be administered in a critical care area such as an Intensive Care Unit (ICU), or other unit with very frequent observation and monitoring. On October 25, 2011, Eli Lilly and Company announced a worldwide voluntary market withdrawal of Xigris [drotrecogin alfa (activated)]. In a 2011 study, Xigris failed to show a survival benefit for patients with severe sepsis and septic shock.
The hydroxamate-based MMP inhibitors display an excellent anticancer activity in tumor cells but the clinical performances of these compounds were disappointing. A factor contributing to this disappointment was that they are broad-spectrum inhibitors of many MMP sub-types that can in many cases also inhibit members of the ADAMs protease family. When they were tested in patients they induced dose-limiting muscular and skeletal pain in a number of the patients. Only when the structures of the MMP inhibitors could be adjusted to impart selectivity and abolish toxicity, would they achieve clinical impact in cancer chemotherapy.
=== Other oxidation states === Although Pd(IV) compounds are comparatively rare, one example is sodium hexachloropalladate(IV), Na2PdCl6. Pd(II) and Pd(IV) can transform into each other under certain electrochemical conditions. A few compounds of palladium(III) are also known. Palladium(VI) was claimed to have been synthesized in 2002, but subsequently disproven. Mixed valence palladium complexes exist, e.g. Pd4(CO)4(OAc)4Pd(acac)2 forms an infinite Pd chain structure, with alternatively interconnected Pd4(CO)4(OAc)4 and Pd(acac)2 units. When alloyed with a more electropositive element, palladium can acquire a negative charge. Such compounds are known as palladides, such as gallium palladide. Palladides with the stoichiometry RPd3 exist where R is scandium, yttrium, or any of the lanthanides.
Caspases play the central role in the transduction of ER apoptotic signals. Caspases are proteins that are highly conserved, cysteine-dependent aspartate-specific proteases. There are two types of caspases: initiator caspases (caspases 2, 8, 9, 10, 11, and 12) and effector caspases (caspases 3, 6, and 7). The activation of initiator caspases requires binding to specific oligomeric activator protein. These active initiator caspases activate the effector caspases through proteolytic cleavage. The active effector caspases then proteolytically degrade a host of intracellular proteins to carry out the cell death program. There also exists a caspase-independent apoptotic pathway that is mediated by AIF (apoptosis-inducing factor).
Sources: en.wikipedia.org
In May 1952, Raymond Gosling, a graduate student working under the supervision of Rosalind Franklin, took an X-ray diffraction image, labeled as "Photo 51", at high hydration levels of DNA. This photo was given to Watson and Crick by Maurice Wilkins and was critical to their obtaining the correct structure of DNA. Franklin told Crick and Watson that the backbones had to be on the outside. Before then, Linus Pauling, and Watson and Crick, had erroneous models with the chains inside and the bases pointing outwards. Franklin's identification of the space group for DNA crystals proved her correct. In February 1953, Linus Pauling and Robert Corey proposed a model for nucleic acids containing three intertwined chains, with the phosphates near the axis, and the bases on the outside. Watson and Crick completed their model, which is now accepted as the first correct model of the double helix of DNA. On 28 February 1953 Crick interrupted patrons' lunchtime at The Eagle pub in Cambridge, England to announce that he and Watson had "discovered the secret of life".
Laboratory testing in the United States is subject to federal regulation. Clinical laboratories performing testing are overseen by the Centers for Medicare and Medicaid Services (CMS) utilizing national standards established under the Clinical Laboratory Improvement Amendments (CLIA). The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) assist CMS in this process. CMS ensures the integrity of laboratories performing testing via inspections and consistent oversight, bolstered with proficiency testing by accredited organizations. CLIA authorizes regulation of laboratories that conduct testing, not the individuals who order the tests or receive test results. All laboratories performing DTC testing must obtain CLIA certification and maintain compliance with national standards.
Shiga toxin type 1 and type 2 (Stx-1 and 2) are the Shiga toxins produced by some E. coli strains. Stx-1 is identical to Stx of Shigella spp. or differs by only one amino acid. Stx-2 shares 55% amino acid homology with Stx-1. Cytotoxins – an archaic denotation for Stx – is used in a broad sense. Verocytotoxins/verotoxins – a seldom-used term for Stx – is from the hypersensitivity of Vero cells to Stx. The term Shiga-like toxins is another antiquated term which arose prior to the understanding that Shiga and Shiga-like toxins were identical.
8. Ir Med J. 2026 Sep 28;119(8):161. Type A Insulin Resistance Syndrome Due to a Pathogenic Variant in the INSR Gene. Afzal S, Brosnan E, Sadiq MS, Rizvi SR, Wassem Z, Iqbal F. PRESENTATION: A woman in her 40s initially diagnosed with type 1 diabetes in 1994 exhibited an atypical 30-year metabolic course, characterised by fluctuating insulin sensitivity, prolonged insulin independence and later insulin resistance despite a non-obese phenotype. DIAGNOSIS: Owing to the unusual clinical trajectory and a strong family history of young-onset diabetes, genetic testing identified a heterozygous pathogenic INSR mutation (p.M1180K), confirming Type A Insulin Resistance Syndrome (TAIRS). TREATMENT: Management evolved from insulin therapy to oral hypoglycaemic agents, including metformin and gliclazide alongside lifestyle modification resulting in partial glycaemic improvement. DISCUSSION: This case underscores the diagnostic challenge of TAIRS, which is frequently misclassified as type 1 or type 2 diabetes and highlights the importance of early genetic evaluation and multidisciplinary care.
Sources: en.wikipedia.org
==== United States ==== 5-MAPB is not an explicitly controlled substance under the United States Controlled Substances Act. It is also not named as a controlled substance under California's Uniform Controlled Substances Act. However, 5-MAPB could be considered a controlled substance as an analogue of MDMA under the United States Federal Analogue Act.
== History == Lethal injection gained popularity in the late 20th century as a form of execution intended to supplant electrocution, gas inhalation, hanging and firing squad, which were considered less humane. It has become the most common form of legal execution in the United States. Lethal injection was proposed on January 17, 1888, by Julius Mount Bleyer, a New York doctor who praised it as being cheaper than hanging. Bleyer's idea would not be revived until the mid-1970s, when Texas and Oklahoma adopted the modern version of the method; a series of botched executions led to an eventual rise of public disapproval of electrocutions in the 1980s. Lethal injections were first used by Nazi Germany to execute prisoners during World War II. Nazi Germany developed the Aktion T4 euthanasia program led by Karl Brandt as one method to terminate Lebensunwertes Leben ("life unworthy of life"). During the war, lethal injections were also administered to children detained at the Sisak concentration camp by the camp's commander, the physician Antun Najžer. The Royal Commission on Capital Punishment 1949–1953 considered lethal injection but eventually ruled it out after pressure from the British Medical Association (BMA).
==== France ==== France was one of the countries that inherited a knowledge of apple cultivation from both the Celtic Gauls and the later Romans, who ruled the country for approximately 500 years: both had knowledge of grafting and keeping apples. The earliest mentions of cider in this country go back to the Greek geographer Strabo: he speaks of the profusion of apple trees in Gaul and describes a cider-like drink. In the 9th century, Charlemagne, in the Capitulars, ordered skilled brewers (the Sicetores) to always be present on his estates to make him ale, "pommé" (pomacium), perry and all the liquors liable to be used as drinks, and also ordered an expansion of planting apple trees in what is now Northern France. French cidre (French pronunciation: [sidʁ]) is an alcoholic drink produced predominantly in Normandy and Brittany. It varies in strength from below 4% alcohol to considerably more. Cidre Doux is a sweet cider, usually up to 3% in strength. 'Demi-Sec' is 3–5% and Cidre Brut is a strong dry cider of 4.5% alcohol and above. Most French ciders are sparkling. Higher quality cider is sold in champagne-style bottles (cidre bouché). Many ciders are sold in corked bottles, but some screw-top bottles exist. In crêperies (crêpe restaurants) in Brittany, cider is generally served in traditional ceramic bowls (or wide cups) rather than glasses. A kir Breton (or kir normand) is a cocktail apéritif made with cider and cassis, rather than white wine and cassis for the traditional kir. The Domfrontais, in the Orne (Basse-Normandie), is famous for its pear cider (poiré).
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。